ChristopherAndrewBarkerMD

Melanoma, Ocular Radiation Oncology, Skin Cancer

Vice Chair for Clinical Research, Associate Attending

Overview of Dr. Barker

Dr. Christopher Barker is a radiation oncologist based in New York, specializing in melanoma, ocular radiation oncology, and skin cancer. He completed his education at the University of Florida College of Medicine in 2006 and undertook his residency and internship at Memorial Sloan Kettering Cancer Center from 2006 to 2011. He is currently a Radiation Oncologist at Memorial Sloan Kettering Cancer Center and has experience in treating conditions such as squamous cell carcinoma, mycosis fungoides, malignant melanoma, and kaposi's sarcoma using techniques such as brachytherapy. Dr. Barker has several notable publications and has been involved in clinical trials mainly aimed at radiation therapy for various types of cancers.

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(210) 529-8158

Education & Training

Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2007 - 2011
Memorial Sloan Kettering Cancer CenterInternship, Transitional Year, 2006 - 2007
University of Florida College of MedicineClass of 2006

Certifications & Licensure

FL State Medical License 2022 - Present
CT State Medical License 2024 - 2025
NJ State Medical License 2015 - 2025
NY State Medical License 2007 - 2025
American Board of Radiology Radiation Oncology

Clinical Trials

Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI) Start of enrollment: 2007 Nov 01
Completed
Neurotropic Melanoma of the Head and Neck Start of enrollment: 2009 Sep 01
Active, not recruiting
Not Applicable
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Start of enrollment: 2013 May 01
Completed
Phase 2
Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma Start of enrollment: 2014 May 01
Active, not recruiting
Not Applicable
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Start of enrollment: 2022 Oct 06
Recruiting
Phase 2
A Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma Start of enrollment: 2022 Mar 03
Recruiting
Phase 2
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma Start of enrollment: 2022 May 17
Recruiting
Phase 2
Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superficial Soft Tissue Tumors Start of enrollment: 2020 Jan 06
Completed
Not Applicable
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Start of enrollment: 2016 Jun 21
Completed
Phase 2
Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients Start of enrollment: 2016 Jun 03
Completed
Phase 2
Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Head and Neck Cancer Start of enrollment: 2016 Oct 03
Recruiting
Phase 2
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma Start of enrollment: 2021 Mar 08
Recruiting
Phase 2
Roles: Contact, Principal Investigator
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma Start of enrollment: 2022 Sep 21
Recruiting
Not Applicable
Roles: Contact
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue Start of enrollment: 2023 Jul 24
Recruiting
Not Applicable
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Minimizing the Morbidity of Mucosal Melanoma With Multimodality Management.
Vonetta M Williams, Christopher A Barker
International Journal of Radiation Oncology, Biology, Physics. 2024-11-15
Reply to M. Boileau et al.
Christopher A Barker, Sue S Yom
Journal of Clinical Oncology. 2024-11-10
A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
Christopher A Barker, Sandra P D'Angelo, Gloria Wasilewski, Alexa M Steckler, Ming Lian
Radiotherapy and Oncology. 2024-11-01

Press Mentions

Vismodegib-RT Regimen Achieves High Rate of Disease Control in Head and Neck BCCMarch 2nd, 2024

Professional Memberships

Insurance Accepted

BCBS Blue Card PPO
CIGNA PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment